接受直接抗病毒药物治疗的晚期丙型肝炎患者中新诊断肝细胞癌:一项前瞻性人群研究
基于意大利威尼托地区NAVIGATORE前瞻性数据库,纳入3917例纤维化分期≥F3、无肝细胞癌(HCC)史的晚期丙型肝炎患者,接受直接抗病毒药物(DAA)治疗,平均随访536.2±197.6天。第一年HCC发生率在F3为0.46%、CTP-A为1.49%、CTP-B为3.61%,第二年分别降至0%、0.2%、0.69%。未获得持续病毒学应答与HCC发生强相关(HR 9.09)。
要点
- 晚期丙肝DAA治疗后第一年HCC风险不高于未治疗患者,可能更低,随后逐年下降。
- 未获得持续病毒学应答者HCC风险显著升高(HR 9.09)。
- 29%的HCC患者为侵袭性肿瘤,常见于治疗早期。
核心结论
- 在晚期丙型肝炎接受DAA治疗的患者中,第一年新发肝细胞癌风险不高于未治疗患者,可能更低,且此后进一步下降。
- 早期出现的肝细胞癌可能反映治疗前已存在的显微镜下不可检测的肿瘤。
研究设计与样本
- 基于意大利威尼托地区NAVIGATORE前瞻性记录数据库的人群研究。
- 纳入标准为纤维化分期≥F3;排除标准为Child-Turcotte-Pugh(CTP)-C级、DAA治疗前肝移植、有肝细胞癌史或现症肝细胞癌、开始DAA后随访<4周。
- 共纳入4234例连续患者中的3917例,平均随访536.2±197.6天。
主要发现
- 共诊断肝细胞癌55例。
- 第一年肝细胞癌发生率:F3为0.46%(95%CI 0.12-1.17),CTP-A为1.49%(95%CI 1.03-2.08),CTP-B为3.61%(95%CI 1.86-6.31)。
- 第二年肝细胞癌发生率:F3为0%,CTP-A为0.2%,CTP-B为0.69%。
- 多因素分析显示肝细胞癌与天冬氨酸氨基转移酶与血小板比值≥2.5(HR 2.03;95%CI 1.14-3.61;p=0.016)及乙型肝炎病毒感染(HR 3.99;95%CI 1.24-12.91;p=0.021)显著相关。
- 未获得持续病毒学应答与肝细胞癌发生强相关(HR 9.09;95%CI 5.2-16.1;p=0.0001)。
关键数值与推荐
- 第一年肝细胞癌发生率:F3为0.46%(95%CI 0.12-1.17),CTP-A为1.49%(95%CI 1.03-2.08),CTP-B为3.61%(95%CI 1.86-6.31)。
- 第二年肝细胞癌发生率:F3为0%,CTP-A为0.2%,CTP-B为0.69%。
- 天冬氨酸氨基转移酶与血小板比值≥2.5的HR为2.03(95%CI 1.14-3.61;p=0.016)。
- 乙型肝炎病毒感染的HR为3.99(95%CI 1.24-12.91;p=0.021)。
- 未获得持续病毒学应答的HR为9.09(95%CI 5.2-16.1;p=0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Direct-acting antiviral agents (DAAs) are safe and effective in patients with hepatitis C. Conflicting data were reported on the risk of hepatocellular carcinoma (HCC) during/after therapy with DAAs. The aim of this study was to evaluate the incidence of newly diagnosed HCC and associated risk factors in patients with advanced hepatitis C treated with DAAs. METHODS: The study is based on the NAVIGATORE platform, a prospectively recording database of all patients with hepatitis C receiving DAAs in the Veneto region of Italy. The inclusion criteria were: fibrosis stage ≥F3. The exclusion criteria were: Child-Turcotte-Pugh (CTP)-C, liver transplantation before DAAs, history or presence of HCC, follow-up <4 weeks after starting DAAs. A total of 3,917 out of 4,234 consecutive patients were included, with a mean follow-up of 536.2 ± 197.6 days. RESULTS: Overall, HCC was diagnosed in 55 patients. During the first year, HCC incidence was 0.46% (95% CI 0.12-1.17) in F3, 1.49% (1.03-2.08) in CTP-A and 3.61% (1.86-6.31) in CTP-B cirrhotics; in the second year, HCC incidences were 0%, 0.2%, and 0.69%, respectively. By multivariate analysis, HCC was significantly associated with an aspartate aminotransferase to platelet ratio ≥2.5 (hazard ratio [HR] 2.03; 95% CI 1.14-3.61; p = 0.016) and hepatitis B virus infection (HR 3.99; 1.24-12.91; p = 0.021). Failure to achieve a sustained virological response was strongly associated with development of HCC (HR 9.09; 5.2-16.1; p = 0.0001). A total of 29% of patients with HCC had an aggressive tumor, often seen in the early phase of treatment. CONCLUSIONS: These data, obtained in a large, prospective, population-based study, indicate that in patients with advanced hepatitis C receiving DAAs, the risk of "de novo" hepatocarcinoma during the first year is not higher, and might be lower, than that of untreated patients. The risk further declines thereafter. Early hepatocarcinoma appearance may reflect pre-existing, microscopic, undetectable tumors. LAY SUMMARY: Hepatocellular carcinoma is one of the complications of hepatitis C related cirrhosis. Treating patients with advanced hepatitis C with the new interferon-free direct-acting antiviral agents has been associated with improvement in liver function and survival, while more conflicting data have been reported regarding the risk of hepatocellular carcinoma. We report the results of a prospective population study on the incidence of newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with direct-acting antiviral agents, clearly indicating that the residual hepatocellular carcinoma risk is reduced and declines progressively with time after a sustained virological response. Development of a liver tumor during/after therapy was associated with known risk factors and with virological failure.
引用
- Romano A, Angeli P, Piovesan S, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol. 2018. PMID: 29551707. doi:10.1016/j.jhep.2018.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。